

Novel combination therapy effective against glioblastoma (GBM)


Inventors: Benjamin Purow, Desiree Floyd, Inan Olmez,
Thurl Harris, Salome Boroda



LICENSING & VENTURES GROUP

Glioblastoma multiforme (GBM)

- GBM is an incurable Grade 4 tumor of the central nervous system
- Comprises about half of all malignant adult primary brain tumors
- Clinical Problem:
 - Currently, the standard regimen of surgery, radiation and temozolomide treatments result in a median survival under 2 years
 - New therapies for GBM have been elusive and are desperately needed




Aboutcancer.com



Combination therapies for GBM

Solution: Researchers at the University of Virginia have shown that a combination of ritanserin, temozolomide, and chloroquine are most effective for GBM treatment.

- Ritanserin is effective synergistically with temozolomide or with chloroquine




Dual-combination treatments for GBM



U251 human glioblastoma cells treated with combinations of ritanserin and chloroquine or temozolomide, demonstrating effectiveness of dual-combination therapies for treatment of GBM.

Dual-combination treatment vs. multi-combination treatment



U251 human glioblastoma cells treated with combinations of ritanserin, chloroquine and temozolomide, demonstrating multi-combination treatment is most effective for treatment of GBM.

Relevant Publication

- Clin Cancer Res. 2015 Nov 15;21(22):5008-12. **Purow B**, et al.

Intellectual Property

- UVA Tech ID: PUROW-RITTEMO
 - Title: Compositions and methods for treating cancer
 - PCT/US2017/026401 Filed on April 6, 2017